|
1
|
Grant EK, Fallon DJ, Hann MM, Fantom KGM, Quinn C, Zappacosta F, Annan RS, Chung C, Bamborough P, Dixon DP, Stacey P, House D, Patel VK, Tomkinson NCO, Bush JT. A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202008361] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Emma K. Grant
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
- Pure and Applied Chemistry University of Strathclyde 295 Cathedral Street Glasgow G1 1XL UK
| | - David J. Fallon
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
- Pure and Applied Chemistry University of Strathclyde 295 Cathedral Street Glasgow G1 1XL UK
| | - Michael M. Hann
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - Ken G. M. Fantom
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - Chad Quinn
- GlaxoSmithKline South Collegeville Road Collegeville PA 19426 USA
| | | | - Roland S. Annan
- GlaxoSmithKline South Collegeville Road Collegeville PA 19426 USA
| | - Chun‐wa Chung
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - Paul Bamborough
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - David P. Dixon
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - Peter Stacey
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - David House
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | | | | | - Jacob T. Bush
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| |
Collapse
|
|
2
|
Grant EK, Fallon DJ, Hann MM, Fantom KGM, Quinn C, Zappacosta F, Annan RS, Chung C, Bamborough P, Dixon DP, Stacey P, House D, Patel VK, Tomkinson NCO, Bush JT. A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands. Angew Chem Int Ed Engl 2020; 59:21096-21105. [DOI: 10.1002/anie.202008361] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Indexed: 12/23/2022]
Affiliation(s)
- Emma K. Grant
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
- Pure and Applied Chemistry University of Strathclyde 295 Cathedral Street Glasgow G1 1XL UK
| | - David J. Fallon
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
- Pure and Applied Chemistry University of Strathclyde 295 Cathedral Street Glasgow G1 1XL UK
| | - Michael M. Hann
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - Ken G. M. Fantom
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - Chad Quinn
- GlaxoSmithKline South Collegeville Road Collegeville PA 19426 USA
| | | | - Roland S. Annan
- GlaxoSmithKline South Collegeville Road Collegeville PA 19426 USA
| | - Chun‐wa Chung
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - Paul Bamborough
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - David P. Dixon
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - Peter Stacey
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | - David House
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| | | | | | - Jacob T. Bush
- GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK
| |
Collapse
|
|
3
|
Teng M, Jiang J, He Z, Kwiatkowski NP, Donovan KA, Mills CE, Victor C, Hatcher JM, Fischer ES, Sorger PK, Zhang T, Gray NS. Development of CDK2 and CDK5 Dual Degrader TMX‐2172. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202004087] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Mingxing Teng
- Department of Cancer Biology Dana-Farber Cancer Institute Harvard Medical School Boston MA USA
- Department of Biological Chemistry and Molecular Pharmacology Harvard Medical School Boston MA USA
| | - Jie Jiang
- Department of Cancer Biology Dana-Farber Cancer Institute Harvard Medical School Boston MA USA
- Department of Biological Chemistry and Molecular Pharmacology Harvard Medical School Boston MA USA
| | - Zhixiang He
- Department of Cancer Biology Dana-Farber Cancer Institute Harvard Medical School Boston MA USA
- Department of Biological Chemistry and Molecular Pharmacology Harvard Medical School Boston MA USA
| | - Nicholas P. Kwiatkowski
- Department of Cancer Biology Dana-Farber Cancer Institute Harvard Medical School Boston MA USA
- Department of Biological Chemistry and Molecular Pharmacology Harvard Medical School Boston MA USA
| | - Katherine A. Donovan
- Department of Cancer Biology Dana-Farber Cancer Institute Harvard Medical School Boston MA USA
- Department of Biological Chemistry and Molecular Pharmacology Harvard Medical School Boston MA USA
| | - Caitlin E. Mills
- Laboratory of Systems Pharmacology Department of Systems Biology Harvard Medical School Boston MA USA
| | - Chiara Victor
- Laboratory of Systems Pharmacology Department of Systems Biology Harvard Medical School Boston MA USA
| | - John M. Hatcher
- Department of Cancer Biology Dana-Farber Cancer Institute Harvard Medical School Boston MA USA
- Department of Biological Chemistry and Molecular Pharmacology Harvard Medical School Boston MA USA
| | - Eric S. Fischer
- Department of Cancer Biology Dana-Farber Cancer Institute Harvard Medical School Boston MA USA
- Department of Biological Chemistry and Molecular Pharmacology Harvard Medical School Boston MA USA
| | - Peter K. Sorger
- Laboratory of Systems Pharmacology Department of Systems Biology Harvard Medical School Boston MA USA
| | - Tinghu Zhang
- Department of Cancer Biology Dana-Farber Cancer Institute Harvard Medical School Boston MA USA
- Department of Biological Chemistry and Molecular Pharmacology Harvard Medical School Boston MA USA
| | - Nathanael S. Gray
- Department of Cancer Biology Dana-Farber Cancer Institute Harvard Medical School Boston MA USA
- Department of Biological Chemistry and Molecular Pharmacology Harvard Medical School Boston MA USA
| |
Collapse
|
|
4
|
Craven GB, Affron DP, Kösel T, Wong TLM, Jukes ZH, Liu CT, Morgan RML, Armstrong A, Mann DJ. Multiparameter Kinetic Analysis for Covalent Fragment Optimization by Using Quantitative Irreversible Tethering (qIT). Chembiochem 2020; 21:3417-3422. [PMID: 32659037 PMCID: PMC7754465 DOI: 10.1002/cbic.202000457] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Indexed: 12/23/2022]
Abstract
Chemical probes that covalently modify cysteine residues in a protein‐specific manner are valuable tools for biological investigations. Covalent fragments are increasingly implemented as probe starting points, but the complex relationship between fragment structure and binding kinetics makes covalent fragment optimization uniquely challenging. We describe a new technique in covalent probe discovery that enables data‐driven optimization of covalent fragment potency and selectivity. This platform extends beyond the existing repertoire of methods for identifying covalent fragment hits by facilitating rapid multiparameter kinetic analysis of covalent structure–activity relationships through the simultaneous determination of Ki, kinact and intrinsic reactivity. By applying this approach to develop novel probes against electrophile‐sensitive kinases, we showcase the utility of the platform in hit identification and highlight how multiparameter kinetic analysis enabled a successful fragment‐merging strategy.
Collapse
Affiliation(s)
- Gregory B Craven
- Department of Life Sciences, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.,Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London, W12 0BZ, UK
| | - Dominic P Affron
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London, W12 0BZ, UK
| | - Teresa Kösel
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London, W12 0BZ, UK
| | - Tsz Lam M Wong
- Department of Life Sciences, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
| | - Zoë H Jukes
- Department of Life Sciences, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
| | - Chun-Ting Liu
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London, W12 0BZ, UK
| | - Rhodri M L Morgan
- Department of Life Sciences, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
| | - Alan Armstrong
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London, W12 0BZ, UK
| | - David J Mann
- Department of Life Sciences, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
| |
Collapse
|
|
5
|
Teng M, Jiang J, He Z, Kwiatkowski NP, Donovan KA, Mills CE, Victor C, Hatcher JM, Fischer ES, Sorger PK, Zhang T, Gray NS. Development of CDK2 and CDK5 Dual Degrader TMX-2172. Angew Chem Int Ed Engl 2020; 59:13865-13870. [PMID: 32415712 DOI: 10.1002/anie.202004087] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Revised: 05/13/2020] [Indexed: 12/12/2022]
Abstract
Cyclin-dependent kinase 2 (CDK2) is a potential therapeutic target for the treatment of cancer. Development of CDK2 inhibitors has been extremely challenging as its ATP-binding site shares high similarity with CDK1, a related kinase whose inhibition causes toxic effects. Here, we report the development of TMX-2172, a heterobifunctional CDK2 degrader with degradation selectivity for CDK2 and CDK5 over not only CDK1, but transcriptional CDKs (CDK7 and CDK9) and cell cycle CDKs (CDK4 and CDK6) as well. In addition, we demonstrate that antiproliferative activity in ovarian cancer cells (OVCAR8) depends on CDK2 degradation and correlates with high expression of cyclin E1 (CCNE1), which functions as a regulatory subunit of CDK2. Collectively, our work provides evidence that TMX-2172 represents a lead for further development and that CDK2 degradation is a potentially valuable therapeutic strategy in ovarian and other cancers that overexpress CCNE1.
Collapse
Affiliation(s)
- Mingxing Teng
- Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Jie Jiang
- Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Zhixiang He
- Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Nicholas P Kwiatkowski
- Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Katherine A Donovan
- Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Caitlin E Mills
- Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA
| | - Chiara Victor
- Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA
| | - John M Hatcher
- Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Eric S Fischer
- Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Peter K Sorger
- Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA
| | - Tinghu Zhang
- Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Nathanael S Gray
- Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| |
Collapse
|